Encompass Health Corporation (EHC) reported $6.34B of revenue for the twelve months ended Sep 30, 2026. That is up 9.4% from the year before. Revenue for fiscal 2025 was $5.94B.

Yes. Encompass Health Corporation earned $644.40M in net income for the twelve months ended Sep 30, 2026, a net margin of 10.2%.

How much cash and debt does EHC have?

Encompass Health Corporation reported $76.20M in cash and cash equivalents and $2.55B of debt on its most recent balance sheet in SEC filings.

How fast is EHC revenue growing?

Encompass Health Corporation's revenue changed +10.5% in fiscal 2025, to $5.94B. Its compound annual growth rate was +10.7% over 5 years and +6.5% over 10 years.

What is EHC free cash flow?

Encompass Health Corporation generated $457.20M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of $1.30B less capital expenditures.

What is EHC earnings per share?

Diluted earnings per share were $6.40 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.

When did EHC last report financial results?

The latest statements here come from Encompass Health Corporation's 10-Q filed on Nov 3, 2026, covering the period ended Sep 30, 2026.

Financials · EHC

Encompass Health Corporation (EHC) financials

For the twelve months ended Sep 30, 2026, Encompass Health Corporation reported $6.34B of revenue and $644.40M of net income.

Revenue, TTM: $6.34B
Revenue growth, YoY: +9.4%
Net income, TTM: $644.40M
Net income growth, YoY: +19.1%
Net margin: 10.2%
Free cash flow, TTM: $457.20M
EPS, diluted, TTM: $6.40
EPS growth, YoY: +21.0%
Cash: $76.20M
Total debt: $2.55B
P/E: 20.94
P/S: 2.13
Market cap: $13.50B

Annual revenue$5.94B

FY2016FY2025

Annual net income$566.20M

FY2016FY2025

Annual free cash flow$439.20M

FY2016FY2025

EHC revenue and earnings growth

EHC revenueQ3 2026$1.61B

Quarter YoY: +8.9%
QoQ: +0.8%
FY YoY: +10.5%
5Y CAGR: +10.7%
10Y CAGR: +6.5%

EHC revenue was $1.61B in fiscal Q3 2026 (ended Sep 30, 2026), up 8.9% from a year earlier and up 0.8% from the prior quarter. For the full fiscal 2025 it was $5.94B, up 10.5% from fiscal 2024. Compound annual growth was +10.7% over 5 years and +6.5% over 10 years. It rose in 9 of the last 10 fiscal years. Fiscal 2025 is the highest of the 15 fiscal years on file.

EHC net incomeQ3 2026$149.90M

Quarter YoY: +18.5%
QoQ: -2.6%
FY YoY: +24.2%
5Y CAGR: +14.8%
10Y CAGR: +12.0%

EHC net income was $149.90M in fiscal Q3 2026 (ended Sep 30, 2026), up 18.5% from a year earlier and down 2.6% from the prior quarter. For the full fiscal 2025 it was $566.20M, up 24.2% from fiscal 2024. Compound annual growth was +14.8% over 5 years and +12.0% over 10 years. It rose in 8 of the last 10 fiscal years. Fiscal 2025 is the highest of the 15 fiscal years on file.

EHC EPSQ3 2026$1.50

Quarter YoY: +21.0%
QoQ: -2.6%
FY YoY: +24.2%
5Y CAGR: +14.2%
10Y CAGR: +11.2%

EHC diluted EPS was $1.50 in fiscal Q3 2026 (ended Sep 30, 2026), up 21.0% from a year earlier and down 2.6% from the prior quarter. For the full fiscal 2025 it was $5.54, up 24.2% from fiscal 2024. Compound annual growth was +14.2% over 5 years and +11.2% over 10 years.

EHC free cash flowQ3 2026$127.50M

Quarter YoY: +52.3%
QoQ: +104.7%
FY YoY: +21.9%
5Y CAGR: +7.1%
10Y CAGR: +1.6%

EHC free cash flow was $127.50M in fiscal Q3 2026 (ended Sep 30, 2026), up 52.3% from a year earlier and up 104.7% from the prior quarter. For the full fiscal 2025 it was $439.20M, up 21.9% from fiscal 2024. Compound annual growth was +7.1% over 5 years and +1.6% over 10 years. It rose in 6 of the last 10 fiscal years.

Export CSV

Income statement

Income statement
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Revenue	$5.94B	$5.37B	$4.80B	$4.35B	$4.01B	$3.57B	$4.61B	$4.28B	$3.91B	$3.64B
Selling, general and admin	$236.20M	$209.20M	$201.70M	$154.30M	$169.50M	$151.60M	$247.00M	$220.20M	$171.70M	$133.40M
Operating income	-	-	-	$539.50M	$559.60M	$563.90M	$612.10M	$555.20M	$578.30M	$588.10M
Interest expense	$123.20M	$137.40M	$143.50M	$175.70M	$164.30M	$183.70M	$159.70M	$147.30M	$154.40M	$172.10M
Pre-tax income	$953.00M	$749.60M	$607.20M	$450.80M	$505.00M	$352.90M	$562.30M	$493.20M	$496.40M	$482.00M
Income tax	$192.90M	$150.20M	$132.20M	$100.10M	$101.90M	$74.70M	$115.90M	$118.90M	$145.80M	$163.90M
Net income	$566.20M	$455.70M	$352.00M	$271.00M	$412.20M	$284.20M	$358.70M	$292.30M	$271.10M	$247.60M
EPS, basic	$5.62	$4.53	$3.51	$2.72	$4.15	$2.87	$3.65	$2.98	$2.88	$2.77
EPS, diluted	$5.54	$4.46	$3.47	$2.70	$4.11	$2.85	$3.61	$2.93	$2.84	$2.59
Diluted shares	102.2M	102.2M	101.3M	100.4M	100.2M	99.8M	99.4M	99.8M	99.3M	99.5M

Balance sheet

Balance sheet
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Cash and equivalents	$72.20M	$85.40M	$69.10M	$21.80M	$49.40M	$185.60M	$60.00M	$69.20M	$54.40M	$40.50M
Receivables	$619.20M	$593.00M	$599.80M	$524.80M	$502.10M	$563.00M	$498.70M	$459.90M	$459.50M	$432.00M
Current assets	$905.90M	$886.90M	$841.80M	$717.20M	$921.40M	$948.60M	$755.80M	$662.10M	$702.20M	$654.50M
Goodwill	$1.32B	$1.28B	$1.28B	$1.26B	$1.24B	$1.23B	$1.22B	$2.10B	$1.97B	$1.93B
Total assets	$7.09B	$6.53B	$6.10B	$5.64B	$6.86B	$6.45B	$6.08B	$5.17B	$4.86B	$4.68B
Current liabilities	$836.40M	$841.00M	$656.40M	$575.90M	$748.80M	$717.30M	$721.00M	$672.50M	$517.50M	$475.60M
Long-term debt	$2.45B	$2.36B	$2.69B	$2.74B	$3.24B	$3.25B	$3.02B	$2.48B	$2.55B	$2.98B
Total debt	$2.45B	$2.36B	$2.69B	$2.74B	$3.24B	$3.25B	$3.02B	$2.48B	$2.55B	$2.98B
Total liabilities	$3.81B	$3.69B	$3.81B	$3.77B	$4.47B	$4.44B	$4.15B	$3.36B	$3.25B	$3.61B
Shareholders' equity	$2.44B	$2.79B	$2.26B	$1.83B	$2.36B	$1.97B	$1.69B	$1.56B	$1.40B	$910.60M

Cash flow

Cash flow
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Operating cash flow	$1.18B	$1.00B	$850.80M	$705.80M	$715.80M	$704.70M	$635.30M	$762.40M	$658.30M	$640.20M
Capital expenditures	$736.40M	$642.50M	$583.10M	$584.10M	$545.70M	$392.80M	$372.40M	$254.50M	$225.80M	$177.70M
Free cash flow	$439.20M	$360.30M	$267.70M	$121.70M	$170.10M	$311.90M	$262.90M	$507.90M	$432.50M	$462.50M
Investing cash flow	-$764.60M	-$653.30M	-$602.80M	-$627.00M	-$666.30M	-$407.50M	-$657.40M	-$424.50M	-$283.00M	-$229.90M
Financing cash flow	-$431.20M	-$330.60M	-$197.20M	-$145.70M	-$240.10M	-$145.90M	$48.20M	-$321.20M	-$359.90M	-$416.40M
Dividends paid	$71.10M	$62.80M	$60.40M	$99.00M	$112.20M	$111.80M	$108.70M	$100.80M	$91.50M	$83.80M
Share repurchases	$158.00M	$31.10M	$0	$0	$0	$6.10M	$45.90M	$0	$38.10M	$65.60M
Stock-based compensation	$56.50M	$48.30M	$50.60M	$29.20M	$29.10M	$25.60M	$114.40M	$85.90M	$47.70M	$27.40M
Depreciation and amortization	$327.90M	$299.60M	$273.90M	$243.60M	$219.60M	$203.00M	$218.70M	$199.70M	$183.80M	$172.60M

Key ratios

Key ratios
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Revenue growth, YoY	10.5%	11.9%	10.4%	8.3%	12.6%	-22.6%	7.7%	9.3%	7.4%	15.2%
Net income growth, YoY	24.2%	29.5%	29.9%	-34.3%	45.0%	-20.8%	22.7%	7.8%	9.5%	35.2%
EPS growth, YoY	24.2%	28.5%	28.5%	-34.3%	44.2%	-21.1%	23.2%	3.2%	9.7%	35.6%
Operating margin	-	-	-	12.4%	13.9%	15.8%	13.3%	13.0%	14.8%	16.1%
Net margin	9.5%	8.5%	7.3%	6.2%	10.3%	8.0%	7.8%	6.8%	6.9%	6.8%
Free cash flow margin	7.4%	6.7%	5.6%	2.8%	4.2%	8.7%	5.7%	11.9%	11.1%	12.7%
Return on equity	23.2%	16.3%	15.6%	14.8%	17.5%	14.4%	21.2%	18.8%	19.4%	27.2%
Return on assets	8.0%	7.0%	5.8%	4.8%	6.0%	4.4%	5.9%	5.6%	5.6%	5.3%
Current ratio	1.08	1.05	1.28	1.25	1.23	1.32	1.05	0.98	1.36	1.38
Debt to equity	1.00	0.84	1.19	1.50	1.37	1.65	1.79	1.59	1.82	3.27

Income statement

Income statement
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023
Revenue	$1.61B	$1.60B	$1.59B	$1.54B	$1.48B	$1.46B	$1.46B	$1.41B	$1.35B	$1.30B	$1.32B	$1.25B
Selling, general and admin	$59.90M	$62.60M	$58.20M	$68.40M	$56.10M	$59.40M	$52.30M	$54.50M	$54.00M	$50.50M	$50.20M	$53.10M
Interest expense	$32.20M	$32.80M	$31.80M	$30.20M	$30.80M	$30.40M	$31.80M	$33.00M	$34.90M	$34.30M	$35.20M	$34.90M
Pre-tax income	$257.80M	$261.60M	$288.70M	$257.70M	$219.90M	$236.80M	$238.60M	$201.40M	$183.80M	$186.00M	$178.40M	$164.80M
Income tax	$53.40M	$53.60M	$56.40M	$55.40M	$44.90M	$51.00M	$41.60M	$37.60M	$36.00M	$38.30M	$38.30M	$37.20M
Net income	$149.90M	$153.90M	$194.50M	$146.10M	$126.50M	$142.10M	$151.50M	$120.90M	$108.20M	$114.10M	$112.50M	$87.60M
EPS, basic	$1.52	$1.55	$1.96	$1.45	$1.26	$1.41	$1.50	$1.20	$1.08	$1.13	$1.12	$0.87
EPS, diluted	$1.50	$1.54	$1.93	$1.43	$1.24	$1.39	$1.48	$1.18	$1.06	$1.12	$1.10	$0.86
Diluted shares	99.7M	100.0M	100.6M	-	102.3M	102.3M	102.1M	-	102.1M	102.0M	102.2M	-

Balance sheet

Balance sheet
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023
Cash and equivalents	$76.20M	$107.70M	$110.50M	$72.20M	$48.70M	$99.10M	$95.80M	$85.40M	$147.80M	$154.40M	$134.40M	$69.10M
Receivables	$712.00M	$687.30M	$676.00M	$619.20M	$610.80M	$612.50M	$623.40M	$593.00M	$576.40M	$589.70M	$619.30M	$599.80M
Current assets	$1.01B	$1.04B	$1.03B	$905.90M	$869.80M	$918.10M	$910.90M	$886.90M	$933.90M	$938.10M	$929.80M	$841.80M
Goodwill	$1.32B	$1.32B	$1.32B	$1.32B	$1.30B	$1.30B	$1.28B	$1.28B	$1.28B	$1.28B	$1.28B	$1.28B
Total assets	$7.57B	$7.46B	$7.31B	$7.09B	$6.87B	$6.79B	$6.64B	$6.53B	$6.46B	$6.39B	$6.23B	$6.10B
Current liabilities	$927.40M	$873.40M	$876.80M	$836.40M	$762.00M	$865.10M	$856.00M	$841.00M	$897.40M	$694.50M	$680.30M	$656.40M
Long-term debt	$2.55B	$2.60B	$2.53B	$2.45B	$2.39B	$2.32B	$2.33B	$2.36B	$2.34B	$2.68B	$2.68B	$2.69B
Total debt	$2.55B	$2.60B	$2.53B	$2.45B	$2.39B	$2.32B	$2.33B	$2.36B	$2.34B	$2.68B	$2.68B	$2.69B
Total liabilities	$4.01B	$4.00B	$3.95B	$3.81B	$3.68B	$3.70B	$3.70B	$3.69B	$3.73B	$3.86B	$3.83B	$3.81B
Shareholders' equity	$2.68B	$3.40B	$3.31B	$2.44B	$3.13B	$3.03B	$2.88B	$2.79B	$2.67B	$2.48B	$2.36B	$2.26B

Cash flow

Cash flow
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023
Operating cash flow	$362.00M	$282.60M	$313.10M	$346.00M	$270.80M	$270.20M	$288.60M	$278.80M	$267.80M	$217.40M	$238.80M	$201.00M
Capital expenditures	$234.50M	$220.30M	$162.40M	$229.30M	$187.10M	$156.90M	$163.10M	$198.70M	$147.50M	$156.90M	$139.40M	$211.70M
Free cash flow	$127.50M	$62.30M	$150.70M	$116.70M	$83.70M	$113.30M	$125.50M	$80.10M	$120.30M	$60.50M	$99.40M	-$10.70M
Investing cash flow	-$241.60M	-$235.60M	-$150.10M	-$239.40M	-$201.30M	-$165.40M	-$158.50M	-$203.70M	-$161.50M	-$158.40M	-$129.70M	-$208.10M
Financing cash flow	-$153.70M	-$76.90M	-$102.50M	-$97.40M	-$113.20M	-$90.20M	-$130.40M	-$150.90M	-$89.50M	-$49.60M	-$40.60M	-$29.90M
Dividends paid	$18.70M	$18.90M	$20.30M	$19.00M	$17.00M	$17.10M	$18.00M	$17.00M	$15.00M	$14.90M	$15.90M	$14.90M
Share repurchases	$57.90M	$74.20M	$71.60M	$76.30M	$24.90M	$24.70M	$32.10M	$7.50M	$6.80M	$16.80M	$0	$0
Stock-based compensation	$15.00M	$13.80M	$11.50M	$18.40M	$14.30M	$14.30M	$9.50M	$12.50M	$12.90M	$13.60M	$9.30M	$13.40M
Depreciation and amortization	$95.70M	$90.40M	$87.30M	$86.40M	$82.40M	$79.90M	$79.20M	$78.00M	$78.40M	$72.90M	$70.30M	$70.10M

Key ratios

Key ratios
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023
Revenue growth, YoY	8.9%	9.6%	9.0%	9.9%	9.4%	12.0%	10.6%	12.7%	11.9%	9.6%	13.4%	9.6%
Net income growth, YoY	18.5%	8.3%	28.4%	20.8%	16.9%	24.5%	34.7%	38.0%	26.8%	24.8%	28.3%	-2.0%
EPS growth, YoY	21.0%	10.8%	30.4%	21.2%	17.0%	24.1%	34.5%	37.2%	26.2%	24.4%	26.4%	-3.4%
Net margin	9.3%	9.6%	12.3%	9.5%	8.6%	9.7%	10.4%	8.6%	8.0%	8.8%	8.5%	7.0%
Free cash flow margin	7.9%	3.9%	9.5%	7.6%	5.7%	7.8%	8.6%	5.7%	8.9%	4.6%	7.6%	-0.9%
Current ratio	1.09	1.19	1.17	1.08	1.14	1.06	1.06	1.05	1.04	1.35	1.37	1.28
Debt to equity	0.95	0.76	0.76	1.00	0.76	0.76	0.81	0.84	0.88	1.08	1.14	1.19

Source: XBRL data Encompass Health Corporation files with the SEC, latest filing dated Nov 3, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

EHC peers

Company	Revenue	Growth	Net income	Net margin	Market cap
EHC	$6.34B	+9.4%	$644.40M	10.2%	$13.50B
HCAHCA Healthcare Inc.	$78.70B	+5.8%	$6.78B	8.6%	$103.40B
THCTenet Healthcare Corporation	$22.15B	+6.2%	$2.90B	13.1%	$22.55B
UHSUniversal Health Services Inc.	$18.35B	+8.0%	$1.46B	8.0%	$11.52B
ENSGThe Ensign Group Inc.	$5.67B	+17.5%	$399.12M	7.0%	$10.56B
PACSPACS Group Inc.	$5.71B	+11.0%	$277.58M	4.9%	$7.87B
NHCNational HealthCare Corporation	$1.58B	+5.6%	$115.13M	7.3%	$3.27B
SGRYSurgery Partners Inc.	$3.37B	+4.0%	-$88.60M	-2.6%	$3.04B
MDPediatrix Medical Group Inc.	$1.96B	+1.9%	$150.09M	7.7%	$2.44B

EHC FAQ

8 questions

What is EHC revenue?
Encompass Health Corporation (EHC) reported $6.34B of revenue for the twelve months ended Sep 30, 2026. That is up 9.4% from the year before. Revenue for fiscal 2025 was $5.94B.
Is EHC profitable?
Yes. Encompass Health Corporation earned $644.40M in net income for the twelve months ended Sep 30, 2026, a net margin of 10.2%.
How much cash and debt does EHC have?
Encompass Health Corporation reported $76.20M in cash and cash equivalents and $2.55B of debt on its most recent balance sheet in SEC filings.
How fast is EHC revenue growing?
Encompass Health Corporation's revenue changed +10.5% in fiscal 2025, to $5.94B. Its compound annual growth rate was +10.7% over 5 years and +6.5% over 10 years.
What is EHC free cash flow?
Encompass Health Corporation generated $457.20M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of $1.30B less capital expenditures.
What is EHC earnings per share?
Diluted earnings per share were $6.40 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
When did EHC last report financial results?
The latest statements here come from Encompass Health Corporation's 10-Q filed on Nov 3, 2026, covering the period ended Sep 30, 2026.
Where does this EHC financial data come from?
Quantisnow builds these statements from the structured XBRL data Encompass Health Corporation files with the SEC. It is provided for information only and is not investment advice.